30 programming-"the"-"DAAD"-"IMPRS-ML"-"U.S"-"PDI-Service"-"Prof" "https:" "UCL" Fellowship positions
Sort by
Refine Your Search
-
). For a full job description please visit UCL’s online recruitment portal (https://www.ucl.ac.uk/work-at-ucl/search-ucl-jobs ) and search using vacancy reference B02-09795. To apply, please upload a current
-
Society until 31 May 2028 in the first instance with the possibility of extension. For a full job description please visit UCL’s online recruitment portal (https://www.ucl.ac.uk/work-at-ucl/search-ucl-jobs
-
posts On-site nursery On-site gym Enhanced maternity, paternity and adoption pay Employee assistance programme: Staff Support Service Discounted medical insurance Visit https://www.ucl.ac.uk/work-at-ucl
-
addressed to Professor Gabriele Lignani (g.lignani at ucl.ac.uk). For a full job description please visit UCL’s online recruitment portal (https://www.ucl.ac.uk/work-at-ucl/search-ucl-jobs ) and search using
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and